Life Technologies Corporation sequence-based system for HLA typing

Thursday, 21 February, 2013 | Supplied by: Life Technologies


Life Technologies Corporation has received US Food and Drug Administration (FDA) 510(k) clearance for its 3500 Dx Genetic Analyzers and SeCore HLA typing kits. The Applied Biosystems 3500 Dx/3500xL Dx CS2 Genetic Analyzers, Invitrogen SeCore HLA Sequencing Kits and uTYPE Dx HLA Sequence Analysis Software constitute the first 510(k)-cleared, sequence-based system for HLA typing in the United States.

Tissue typing is an essential component of determining compatibility between donors and patients for organ and bone marrow transplantation. HLA typing on the 3500 Dx offers labs an optimised, streamlined workflow said to have higher resolution than other molecular HLA typing technologies such as sequence-specific oligonucleotide (SSO) methods.

Online: www.invitrogen.com
Phone: 1800 331 627
Related Products

Lonza 4D-Nucleofector LV Unit PRO electroporation unit

Lonza's 4D-Nucleofector LV Unit PRO is a next-generation, large-scale electroporation unit...

Cytek 25-Color Immunoprofiling Assay, cFluor Reagent Kit (18C)

The Cytek 25-Color Immunoprofiling Assay has been designed and optimised to provide a turnkey...

Bio-Rad Laboratories QX Continuum and QX700 series ddPCR platforms

The latest platforms complement Bio-Rad's existing QX ddPCR portfolio and offer users...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd